Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$97.14M
EBITDA Margin
-1299.47%
TTM Avg
-2594.80%
3Y Avg
-2594.80%
5Y Avg
-1753.28%
Market Cap
$95.14M
EBITDA Margin
-4034.35%
TTM Avg
-4034.35%
3Y Avg
-3775.34%
5Y Avg
-2903.14%
Market Cap
$102.75M
EBITDA Margin
-5221.43%
TTM Avg
-5221.43%
3Y Avg
-3887.65%
5Y Avg
-3386.47%
Market Cap
$92.69M
EBITDA Margin
5.05%
TTM Avg
6.33%
3Y Avg
5.80%
5Y Avg
5.80%
Market Cap
$103.14M
EBITDA Margin
28.85%
TTM Avg
28.85%
3Y Avg
28.85%
5Y Avg
28.85%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PolyPid Ltd. (PYPD) | $97.90M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $97.94M | N/A | N/A | N/A | N/A |
| Korro Bio, Inc. (KRRO)vs › | $97.14M | -1299.47% | -2594.80% | -2594.80% | -1753.28% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $99.62M | N/A | N/A | N/A | N/A |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $95.14M | -4034.35% | -4034.35% | -3775.34% | -2903.14% |
| The Joint Corp. (JYNT)vs › | $101.36M | 1.47% | 3.45% | 8.31% | 9.97% |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.75M | -5221.43% | -5221.43% | -3887.65% | -3386.47% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $92.69M | 5.05% | 6.33% | 5.80% | 5.80% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $103.14M | 28.85% | 28.85% | 28.85% | 28.85% |
| Definitive Healthcare Corp. (DH)vs › | $104.26M | 6.31% | -127.53% | -89.97% | -50.55% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
